ZURA vs. MESO, TCRX, ALVR, ERYP, CMPX, HARP, STRO, IVVD, GNFT, and CLLS
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Mesoblast (MESO), TScan Therapeutics (TCRX), AlloVir (ALVR), ERYTECH Pharma (ERYP), Compass Therapeutics (CMPX), Harpoon Therapeutics (HARP), Sutro Biopharma (STRO), Invivyd (IVVD), Genfit (GNFT), and Cellectis (CLLS). These companies are all part of the "biological products, except diagnostic" industry.
Mesoblast (NASDAQ:MESO) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.
Mesoblast received 393 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 71.23% of users gave Mesoblast an outperform vote.
2.6% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 15.8% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Mesoblast presently has a consensus target price of $7.13, suggesting a potential upside of 393.08%. Zura Bio has a consensus target price of $16.60, suggesting a potential upside of 265.64%. Given Zura Bio's higher possible upside, equities analysts clearly believe Mesoblast is more favorable than Zura Bio.
Zura Bio has lower revenue, but higher earnings than Mesoblast.
Mesoblast has a beta of 3.39, meaning that its share price is 239% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
Zura Bio has a net margin of 0.00% compared to Zura Bio's net margin of -1,061.43%. Zura Bio's return on equity of -16.32% beat Mesoblast's return on equity.
In the previous week, Mesoblast had 4 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Mesoblast and 1 mentions for Zura Bio. Mesoblast's average media sentiment score of 1.35 beat Zura Bio's score of -0.45 indicating that Zura Bio is being referred to more favorably in the news media.
Summary
Mesoblast beats Zura Bio on 9 of the 16 factors compared between the two stocks.
Get Zura Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Zura Bio Competitors List
Related Companies and Tools